ATE419866T1 - Verfahren zur expression von antigenen auf der oberfläche der antigen-präsentierenden zellen durch photochemische internalisation - Google Patents

Verfahren zur expression von antigenen auf der oberfläche der antigen-präsentierenden zellen durch photochemische internalisation

Info

Publication number
ATE419866T1
ATE419866T1 AT00909489T AT00909489T ATE419866T1 AT E419866 T1 ATE419866 T1 AT E419866T1 AT 00909489 T AT00909489 T AT 00909489T AT 00909489 T AT00909489 T AT 00909489T AT E419866 T1 ATE419866 T1 AT E419866T1
Authority
AT
Austria
Prior art keywords
antigen
presenting cells
expressing antigens
photochemical internalization
cell
Prior art date
Application number
AT00909489T
Other languages
English (en)
Inventor
Kristian Berg
Torunn Tjelle
Anders Hogset
Lina Prasmickaite
Original Assignee
Pci Biotech As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pci Biotech As filed Critical Pci Biotech As
Application granted granted Critical
Publication of ATE419866T1 publication Critical patent/ATE419866T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00909489T 1999-03-15 2000-03-10 Verfahren zur expression von antigenen auf der oberfläche der antigen-präsentierenden zellen durch photochemische internalisation ATE419866T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9905911.5A GB9905911D0 (en) 1999-03-15 1999-03-15 Method

Publications (1)

Publication Number Publication Date
ATE419866T1 true ATE419866T1 (de) 2009-01-15

Family

ID=10849643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00909489T ATE419866T1 (de) 1999-03-15 2000-03-10 Verfahren zur expression von antigenen auf der oberfläche der antigen-präsentierenden zellen durch photochemische internalisation

Country Status (19)

Country Link
US (2) US8216587B1 (de)
EP (1) EP1223973B1 (de)
JP (1) JP4922490B2 (de)
KR (1) KR100769113B1 (de)
CN (1) CN100379450C (de)
AT (1) ATE419866T1 (de)
AU (1) AU771990B2 (de)
CA (1) CA2367357C (de)
CZ (1) CZ299370B6 (de)
DE (1) DE60041347D1 (de)
DK (1) DK1223973T3 (de)
ES (1) ES2319255T3 (de)
GB (1) GB9905911D0 (de)
HU (1) HU227604B1 (de)
MX (1) MXPA01009316A (de)
NO (1) NO331101B1 (de)
NZ (1) NZ514228A (de)
PL (1) PL208221B1 (de)
WO (1) WO2000054802A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002222104B2 (en) 2000-11-29 2007-06-28 Pci Biotech As Photochemical internalization for virus-mediated molecule delivery into the cyosol
CZ301427B6 (cs) 2000-11-29 2010-02-24 Pci Biotech As Zpusob zavedení molekuly do cytosolu bunky
AU2002250034A1 (en) * 2001-02-08 2002-08-19 Sequitur, Inc. Methods of light activated release 0f ligands from endosomes
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064625A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
GB0613753D0 (en) 2006-07-11 2006-08-23 Norwegian Radium Hospital Res Method
MX2009003764A (es) 2006-10-04 2009-04-22 Janssen Pharmaceutica Nv Preparaciones de celulas presentadoras de antigeno artificiales y su uso en terapias celulares.
GB0811955D0 (en) * 2008-06-30 2008-07-30 Pci Biotech As Method
GB0914287D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Compositions
GB0914286D0 (en) 2009-08-14 2009-09-30 Pci Biotech As Method
GB201208548D0 (en) * 2012-05-15 2012-06-27 Pci Biotech As Compound and method
US20160040128A1 (en) * 2013-03-15 2016-02-11 Pci Biotech As Method
CA2922320C (en) * 2013-08-28 2022-11-22 Pci Biotech As Enhanced photochemical internalisation using a tlr ligand
WO2015028575A1 (en) * 2013-08-28 2015-03-05 Pci Biotech As Immunisation method by photochemical internalisation
GB2517707B (en) * 2013-08-28 2020-09-02 Pci Biotech As A device for light-induced rupture of endocytic vesicles to effect the delivery of an antigen
CA2945220C (en) * 2014-04-11 2023-09-26 Pci Biotech As Method of treating melanoma
GB201415250D0 (en) * 2014-08-28 2014-10-15 Pci Biotech As Compound and method
NZ729408A (en) 2014-08-28 2021-12-24 Pci Biotech As A method of photochemical internalization (pci) utilizing a antigenic molecule, a photosensitizing agent, and a cytokine
GB201503776D0 (en) 2015-03-05 2015-04-22 Pci Biotech As Compound and method
KR20190068573A (ko) 2016-10-14 2019-06-18 피씨아이 바이오테크 에이에스 젬시타빈의 tpcs-2a 유도된 광화학 내재화로의 담관암의 치료
CN107029236B (zh) * 2017-04-18 2020-04-10 中国医学科学院生物医学工程研究所 一种吲哚菁绿自组装纳米疫苗及制备方法
CN107217041B (zh) * 2017-07-11 2020-05-15 深圳华云生物技术有限公司 具有高抗原呈递的dc细胞和抗原特异性t细胞及其制备方法和应用
GB201718631D0 (en) 2017-11-10 2017-12-27 Pci Biotech As Method
EP3823668A1 (de) 2018-07-16 2021-05-26 DCPrime B.V. Kombinationsprodukt zur verwendung in der tumorimpfung
JP2022530044A (ja) 2019-04-25 2022-06-27 ディーシープライム・ベスローテン・フェンノートシャップ 腫瘍ワクチン接種方法
EP4127139A1 (de) 2020-03-27 2023-02-08 Mendus B.V. Ex-vivo-verwendung modifizierter zellen leukämischen ursprungs zur verbesserung der wirksamkeit einer adoptiven zelltherapie
WO2021191871A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
GB202101726D0 (en) 2021-02-08 2021-03-24 Pci Biotech As Method
GB202115451D0 (en) 2021-10-27 2021-12-08 Pci Biotech As Method
GB202301312D0 (en) 2023-01-30 2023-03-15 Pci Biotech As Method and product

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
US5820872A (en) * 1992-11-18 1998-10-13 Yale University Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor
US5651993A (en) * 1992-11-18 1997-07-29 Yale University Specific immune system modulation
NO180167C (no) * 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
US6008211A (en) * 1995-07-27 1999-12-28 Pdt Pharmaceuticals, Inc. Photoactivatable compounds comprising benzochlorin and furocoumarin
ES2171022T3 (es) * 1997-05-07 2002-08-16 Quadra Logic Tech Inc Esteres de etilenglicol de derivados de monohidrobenzoporfirinas como agentes fotoactivos.
CZ301427B6 (cs) 2000-11-29 2010-02-24 Pci Biotech As Zpusob zavedení molekuly do cytosolu bunky
GB201208548D0 (en) 2012-05-15 2012-06-27 Pci Biotech As Compound and method
CA2922320C (en) 2013-08-28 2022-11-22 Pci Biotech As Enhanced photochemical internalisation using a tlr ligand

Also Published As

Publication number Publication date
KR100769113B1 (ko) 2007-10-22
PL208221B1 (pl) 2011-03-31
AU3177100A (en) 2000-10-04
EP1223973B1 (de) 2009-01-07
ES2319255T3 (es) 2009-05-06
US8216587B1 (en) 2012-07-10
CZ299370B6 (cs) 2008-07-09
HUP0202441A2 (en) 2002-10-28
CZ20013328A3 (cs) 2002-03-13
US20130330363A1 (en) 2013-12-12
NO331101B1 (no) 2011-10-03
HUP0202441A3 (en) 2004-07-28
GB9905911D0 (en) 1999-05-05
KR20010110664A (ko) 2001-12-13
CN100379450C (zh) 2008-04-09
HU227604B1 (en) 2011-09-28
DK1223973T3 (da) 2009-05-04
WO2000054802A3 (en) 2002-05-10
PL355015A1 (en) 2004-03-22
NO20014491L (no) 2001-11-14
US9737594B2 (en) 2017-08-22
MXPA01009316A (es) 2003-07-14
CA2367357A1 (en) 2000-09-21
WO2000054802A2 (en) 2000-09-21
JP2002541072A (ja) 2002-12-03
CN1376073A (zh) 2002-10-23
AU771990B2 (en) 2004-04-08
JP4922490B2 (ja) 2012-04-25
NZ514228A (en) 2004-01-30
NO20014491D0 (no) 2001-09-14
CA2367357C (en) 2015-01-06
DE60041347D1 (de) 2009-02-26
EP1223973A2 (de) 2002-07-24

Similar Documents

Publication Publication Date Title
ATE419866T1 (de) Verfahren zur expression von antigenen auf der oberfläche der antigen-präsentierenden zellen durch photochemische internalisation
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
DE69732407D1 (de) Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren
BR0015501A (pt) Compostos de aminoalquil glucosaminida fosfato e uso dos mesmos como adjuvantes e agentes de efeito imune
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
BR9809656A (pt) Composição imunopotencializante
DE69133228D1 (de) Dna-expressionssysteme basierend auf alphaviren
ATE345682T1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
ATE319745T1 (de) Verfahren zur herstellung von nicht-immunogenen proteinen
ZA831833B (en) New conjugates associating,by covalent bond,an enzyme with an antibody,and medicinal associations using the said conjugates
ES2153034T3 (es) Sistema de suministro en microparticulas.
ATE358873T1 (de) Verfahren zum anbringen von markierungen auf optische medienartikel
ATE314462T1 (de) Verfahren zur transformation dendritischer zellen und aktivierung von t zellen
MX2020009825A (es) Glicoconjugados de precision como herramientas terapeuticas.
ATE538811T1 (de) Zytotoxizitätsvermittlung von zellen mit hinweisen auf oberflächenexpression von cd44
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
DE602005007177D1 (de) Komplexe mit adjuvanter wirkung
ATE254137T1 (de) ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
AR011740A1 (es) Proteinas del virus que produce enrollamiento en las hojas de la vid del tipo 2, secuencias de codificacion y metodos
ATE417112T1 (de) Steigerung der immunantwort unter verwendung von zielgerichteten molekülen
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DE60031147D1 (de) Verfahren zum generieren von informationen in zusammenhang mit der molekularstruktur eines biomoleküls
DE3854096D1 (de) Verfahren zur Isolierung von Basalmembranproteinen aus menschlichen und tierischen Geweben.
DE60011785D1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
DE60035504D1 (de) Verfahren für die verabreichung von heilmitteln mittels einer dextrinlösung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1223973

Country of ref document: EP